Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease

Nature Reviews Clinical Oncology

Volumn 13, Issue 7, 2016, Pages 401-402

  Rosell, Rafael ^a   Karachaliou, Niki ^b,c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Germans Trias i Pujol Health Sciences Institute and Hospital   (Spain)

^c HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; RAS PROTEIN;

ADVANCED CANCER; CANCER PROGNOSIS; DNA SEQUENCE; EGFR GENE; EXON; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; LIQUID BIOPSY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; ONCOGENE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; TUMOR BIOPSY; TUMOR VOLUME; GENETICS; LUNG TUMOR; MUTATION;

HUMANS; LUNG NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84975458345     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.83     Document Type: Review

References (10)

1. Sacher, A. G. et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. http:// dx.doi.org/10.1001/jamaoncol.2016.0173 (2016).
2. Kalikaki, A. et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br. J. Cancer 99, 923-929 (2008).
3. Karachaliou, N. et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC Trial. JAMA Oncol. 1, 149-157 (2015).
4. Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
5. Diaz, L. A. Jr et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
6. Rosell, R. et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361, 958-967 (2009).
7. Gautschi, O. et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett. 254, 265-273 (2007).
8. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426-437 (2011).
9. Thress, K. S. et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer 90, 509-515 (2015).
10. Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924-3933 (2015).